| 0.7913 0.032 (4.16%) | 06-17 13:15 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.14 | 1-year : | 1.33 |
| Resists | First : | 0.98 | Second : | 1.13 |
| Pivot price | 0.83  |
|||
| Supports | First : | 0.73 | Second : | 0.6 |
| MAs | MA(5) : | 0.77 |
MA(20) : | 0.88 |
| MA(100) : | 1.05 |
MA(250) : | 1.04 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.4 |
D(3) : | 7.5 |
| RSI | RSI(14): 40.4 |
|||
| 52-week | High : | 3.86 | Low : | 0.38 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RANI ] has closed above bottom band by 30.4%. Bollinger Bands are 20.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.78 - 0.79 | 0.79 - 0.79 |
| Low: | 0.72 - 0.72 | 0.72 - 0.73 |
| Close: | 0.75 - 0.76 | 0.76 - 0.77 |
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Tue, 16 Jun 2026
RANI SEC Filings - Rani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 12 Jun 2026
RANI Stock Price, Quote & Chart - ChartMill
Thu, 11 Jun 2026
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Fri, 05 Jun 2026
Rani Therapeutics (NASDAQ: RANI) CTO awarded 805,500 stock options - Stock Titan
Mon, 01 Jun 2026
Imran Mir A of Rani Therapeutics (NASDAQ: RANI) receives 123,600 stock options - Stock Titan
Tue, 26 May 2026
Sovereign wealth fund leads $20M raise for oral drug delivery firm - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 112 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 43.8 (%) |
| Shares Short | 7,380 (K) |
| Shares Short P.Month | 8,950 (K) |
| EPS | -0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.28 |
| Profit Margin | 0 % |
| Operating Margin | -488.3 % |
| Return on Assets (ttm) | -57 % |
| Return on Equity (ttm) | -240 % |
| Qtrly Rev. Growth | 893 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -2.93 |
| PEG Ratio | 0 |
| Price to Book value | 2.81 |
| Price to Sales | 27.97 |
| Price to Cash Flow | -5.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|